Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-D...
Bio Usawa, a leader in expanding global access to biopharmaceuticals, and Nanoly Bioscience, a pioneer in chemical stabilization, announced a defin...
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1 Remibrutinib, a hi...
Endoplasmic reticulum (ER) stress and the unfolded protein response are often implicated in the progression of metabolic dysfunction-associated stea...
Sapu Bioscience announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, stre...
InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced &nb...
MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years – &nda...
MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative disea...
-Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medi...
Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic...
Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabete...
Australian company Ferronova announced it has completed enrolment of patients for its two-year trial to progress commercialisation of FerroTrace, a ...
In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significant...
Agreement will leverage Evinova’s innovative AI-native platform to improve trial design, accelerate timelines, and enhance cost efficiency ...
© 2026 Biopharma Boardroom. All Rights Reserved.
